Terazosin HClCAS# 70024-40-7 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 70024-40-7 | SDF | Download SDF |
| PubChem ID | 63016 | Appearance | Powder |
| Formula | C19H30ClN5O6 | M.Wt | 459.92 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (108.71 mM; Need ultrasonic) H2O : 12.5 mg/mL (27.18 mM; Need ultrasonic) | ||
| Chemical Name | [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone;dihydrate;hydrochloride | ||
| SMILES | [H+].O.O.[Cl-].COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4 | ||
| Standard InChIKey | NZMOFYDMGFQZLS-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Terazosin HCl Dilution Calculator
Terazosin HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1743 mL | 10.8715 mL | 21.7429 mL | 43.4858 mL | 54.3573 mL |
| 5 mM | 0.4349 mL | 2.1743 mL | 4.3486 mL | 8.6972 mL | 10.8715 mL |
| 10 mM | 0.2174 mL | 1.0871 mL | 2.1743 mL | 4.3486 mL | 5.4357 mL |
| 50 mM | 0.0435 mL | 0.2174 mL | 0.4349 mL | 0.8697 mL | 1.0871 mL |
| 100 mM | 0.0217 mL | 0.1087 mL | 0.2174 mL | 0.4349 mL | 0.5436 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Terazosin HCl dihydrate is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH).
- 2-Adamantanone
Catalog No.:BCN8473
CAS No.:700-58-3
- 2-Adamantanol
Catalog No.:BCN8479
CAS No.:700-57-2
- Indole-3-carbinol
Catalog No.:BCC5318
CAS No.:700-06-1
- H-Tyr(3-I)-OH
Catalog No.:BCC3265
CAS No.:70-78-0
- 1-(4-Hydroxyphenyl)propan-1-one
Catalog No.:BCN4597
CAS No.:70-70-2
- H-Asn-OH
Catalog No.:BCC2875
CAS No.:70-47-3
- L-Glutathione Reduced
Catalog No.:BCC8030
CAS No.:70-18-8
- Triflurdine (Viroptic)
Catalog No.:BCC3873
CAS No.:70-00-8
- Isocostic acid
Catalog No.:BCN4260
CAS No.:69978-82-1
- 20(S),24(R)-Ocotillol
Catalog No.:BCN3891
CAS No.:69926-31-4
- Swertisin
Catalog No.:BCN2762
CAS No.:6991-10-2
- Cyanopindolol hemifumarate
Catalog No.:BCC6880
CAS No.:69906-86-1
- Rivularin
Catalog No.:BCN3189
CAS No.:70028-59-0
- LPYFD-NH2
Catalog No.:BCC6113
CAS No.:700361-48-4
- 4,10-Aromadendranediol
Catalog No.:BCN4261
CAS No.:70051-38-6
- Acronycine
Catalog No.:BCC8114
CAS No.:7008-42-6
- LY2109761
Catalog No.:BCC3806
CAS No.:700874-71-1
- LY2157299
Catalog No.:BCC3709
CAS No.:700874-72-2
- TCN 237 dihydrochloride
Catalog No.:BCC6111
CAS No.:700878-19-9
- 5-Heneicosylresorcinol
Catalog No.:BCN7630
CAS No.:70110-59-7
- 5-Tricosyl-1,3-benzenediol
Catalog No.:BCN4262
CAS No.:70110-60-0
- 5-Pentacosylresorcinol
Catalog No.:BCN4263
CAS No.:70110-61-1
- BMS-626529
Catalog No.:BCC1427
CAS No.:701213-36-7
- DGAT-1 inhibitor
Catalog No.:BCC1529
CAS No.:701232-20-4
Alpha 1-adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain.[Pubmed:1347941]
Prostate. 1992;20(2):159-65.
The objective of the present study was to characterize the alpha 1-adrenoceptor binding properties of terazosin and its enantiomers in human prostate and canine brain. Human prostate adenomas were obtained from 7 males undergoing prostatectomy for symptomatic BPH and canine cerebral cortices were obtained from 6 male beagles. Competitive displacement experiments were carried out on these tissue homogenates in the presence of a constant concentration ([180 pM]) of 125I-Heat and varying concentrations of unlabelled terazosin and its enantiomers. The Ki of terazosin and its enantiomers were determined from these binding studies. The mean Ki of rac-terazosin, R(+)-terazosin, and S(-)-terazosin in human prostate was 3.6 nM, 3.8 nM, and 2.8 nM, respectively. The differences between these mean Ki values were not statistically significant. The mean Ki of rac-terazosin, R(+)-terazosin, and S(-)-terazosin in canine brain were 6.7 nM, 8.4 nM, and 5.6 nM, respectively. The differences between these mean Ki values were not significantly different. The mean Ki of terazosin and its enantiomers were consistently lower in the human prostate compared to canine brain (P less than 0.05). The present study does not provide any evidence suggesting differential effects of terazosin enantiomers on the human prostate. The twofold difference between the Ki values in the prostate and brain suggests that different subtypes of the alpha 1-receptor might be present in these tissues.
